11.15.16
Biogen has added two members to the executive management team of Bioverativ Inc., Biogen’s planned spin-off focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer, and John T. Greene will serve as executive vice president and chief financial officer. The spin-off is scheduled to be completed in early 2017.
“Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” said George A. Scangos, Ph.D., chief executive officer of Biogen.
“Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.” “Rogerio’s expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients,” said John Cox, chief executive officer of Bioverativ. “And, given John’s strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to Lead our global finance organization and be an excellent representative for our shareholders.”
Dr. Vivaldi has more than 20 years of experience developing orphan products, most notably during his tenure at Genzyme Corp., where he lead the company's rare disease business. Most recently, he served as chief commercial officer at Spark Therapeutics , a Gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences. Dr. Vivaldi will be responsible for building and leading all aspects of Bioverativ’s commercial organization, including oversight of sales and marketing for the franchise’s lead products, ELOCTATE and ALPROLIX, extended Half-Life therapies for the treatment of hemophilia A and hemophilia B, respectively. He will report to Bioverativ CEO John Cox.
Mr. Greene joins Bioverativ from Willis Group, plc, where he served as chief financial officer, enhancing business analytics and company performance and helping to execute a merger and acquisition program. Previously, he was chief financial officer for HSBC Holdings. Mr. Greene will be responsible for all financial and fiscal management of Bioverativ’s operations, with oversight for the company’s finance, information technology and technical operations functions. He will also work closely with business development, and research and development to grow the business. He will also report to Mr. Cox.
“Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” said George A. Scangos, Ph.D., chief executive officer of Biogen.
“Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.” “Rogerio’s expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients,” said John Cox, chief executive officer of Bioverativ. “And, given John’s strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to Lead our global finance organization and be an excellent representative for our shareholders.”
Dr. Vivaldi has more than 20 years of experience developing orphan products, most notably during his tenure at Genzyme Corp., where he lead the company's rare disease business. Most recently, he served as chief commercial officer at Spark Therapeutics , a Gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences. Dr. Vivaldi will be responsible for building and leading all aspects of Bioverativ’s commercial organization, including oversight of sales and marketing for the franchise’s lead products, ELOCTATE and ALPROLIX, extended Half-Life therapies for the treatment of hemophilia A and hemophilia B, respectively. He will report to Bioverativ CEO John Cox.
Mr. Greene joins Bioverativ from Willis Group, plc, where he served as chief financial officer, enhancing business analytics and company performance and helping to execute a merger and acquisition program. Previously, he was chief financial officer for HSBC Holdings. Mr. Greene will be responsible for all financial and fiscal management of Bioverativ’s operations, with oversight for the company’s finance, information technology and technical operations functions. He will also work closely with business development, and research and development to grow the business. He will also report to Mr. Cox.
